Abiopharma

🔍 Kaul Inderjit (Executive)

Company: Minerva Neurosciences, Inc. (NERV)

Report Date: 2026-08-03

Detailed Transactions and Holdings:

• Acquired 12,147 shares of Stock Option (right to buy) at $3.97 per share (Derivative)
  Date: 2026-08-03 | Code: A | Expires: 2036-08-02 | equity_swap_involved: 0 | shares_owned_after: 12,147.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: 25% of the option shall vest on November 14, 2026; an additional 45% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date.